Skip to main content
. 2020 Jan 21;11(3):237–249. doi: 10.18632/oncotarget.27428

Figure 4.

Figure 4

Association of (AC) VHL mutations and (DF) VHL deletions (3p) in papillary carcinoma and overall survival (A, D), relapse-free survival (B, E), and cancer specific death (C, F).